Influenza Vaccine Development
Trivalent influenza vaccine safe in healthy children
Published in Vaccine Weekly, October 26th, 2005
"Influenza-associated deaths in healthy children that were reported during the 2003 2004 influenza season heightened the public awareness of the seriousness of influenza in children. In 1996-1998, a pivotal phase III trial was conducted in children who were 15 to 71 months of age. Live attenuated influenza vaccine, trivalent (LAIV-T), was shown to be safe and efficacious," scientists in the United States report.
"In a subsequent randomized, double-blind, placebo-controlled LAIV-T trial in children who were 1 to 17 years of age, a statistically significant increase in asthma...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-10-26)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine Development
Efficacy of recombinant glycoprotein 120 vaccine reported - Herpes Vaccine Development
HSV-1 gC-1 immunization may stimulate antibodies that modify disease - Malaria Vaccine Development
P36p-deficient malarial sporozoites protect infected liver cells - Smallpox Vaccine
Clinical responses to smallpox vaccine examined - Allergy & Immunology
Frequency of antigen-specific CD4+ T cells affects allergic airway inflammation - Anthrax Vaccines
Reports advance knowledge in anthrax vaccines research - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
